Can a leukemia drug flush out HIV's last hiding spots?

NCT ID NCT07481175

Recruiting now Disease control Sponsor: Thomas Aagaard Rasmussen Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 23, 2026 · Updated 15 times

Summary

This early-stage study tests whether adding the drug venetoclax to standard HIV treatment can help kill cells that harbor dormant HIV. The goal is to shrink the hidden virus reservoir, which is the main barrier to a cure. About 38 adults newly starting HIV therapy will receive venetoclax or standard care, and researchers will monitor safety and changes in the size of the HIV reservoir.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases
RECRUITING

Badalona, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Infectious Diseases, Q Research
RECRUITING

Aarhus, 8200, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIV-1